Literature DB >> 23464409

Second primary malignant neoplasms: a clinicopathological analysis from a cancer centre in India.

Narendra Hulikal1, Satadru Ray, Joseph Thomas, Donald J Fernandes.   

Abstract

CONTEXT: Patients diagnosed with a cancer have a life time risk of developing another de novo malignancy depending on various inherited, environmental and iatrogenic risk factors. Of late the detection of new primary has increased mainly due to refinement in both diagnostic and treatment modalities. Cancer victims are surviving longer and thus are more likely to develop a new metachronous malignancy. AIMS: To report our observed trend of increase in prevalence of both synchronous and metachronous second malignant neoplasms among cancer victims and to review the relevant literature. SETTINGS AND
DESIGN: A hospital based retrospective collection of prospective data of patients diagnosed with second denovo malignancy. MATERIALS AND
METHOD: The study was conducted over a 5 year period from July 2008 to June 2012. All patients diagnosed with a histologically proven second malignancy as per Warren Gate's criteria were included. Various details regarding sex, age at presentation, synchronous or metachronous, treatment and outcome were recorded.
CONCLUSIONS: The occurrence of multiple primary malignancies is not rare. Awareness of the possibility alerts the clinician in evaluation of patients with a known malignancy presenting with unusual sites of metastasis. Individualizing the treatment according to the stages of the primaries will result in durable cancer control particularly in synchronous double malignancy.

Entities:  

Mesh:

Year:  2012        PMID: 23464409     DOI: 10.7314/apjcp.2012.13.12.6087

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  7 in total

1.  CML as Part of Dual Malignancies-A Retrospective Analysis: Possible Mechanisms and Review of Literature.

Authors:  Kamal Kant Sahu; Yanamandra Uday; Amanjit Bal; Neelam Varma; Shano Naseem; Alka Khadwal; Gaurav Prakash; S Varma; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2015-11-21       Impact factor: 0.900

2.  Synchronous Primary Endometrial Carcinoma and Metastatic Malignant Melanoma in Cervical Lymph Node.

Authors:  Kanwardeep Tiwana; Sarita Nibhoria; Manmeet Kaur; Saloni Bansal
Journal:  J Clin Diagn Res       Date:  2017-05-01

3.  Multidisciplinary treatment based on surgery leading to long-term survival of a patient with multiple asynchronous rare primary malignant neoplasms: A case report and literature review.

Authors:  Hong-Lin Gu; Shi-Xing Zeng; Yun-Bing Chang; Zhen Lin; Qiu-Jian Zheng; Xiao-Qing Zheng; Zhen-Wei Peng; Shi-Qiang Zhan
Journal:  Oncol Lett       Date:  2014-12-29       Impact factor: 2.967

4.  Double primary malignancies: a clinical & pathological analysis report from a regional cancer institute in India.

Authors:  Puneet Kumar Bagri; Daleep Singh; Mukesh Kumar Singhal; Guman Singh; Gaurav Mathur; Shankar Lal Jakhar; Surender Beniwal; Neeti Sharma; Harvindra Singh Kumar; Ajay Sharma; Megh Raj Bardia
Journal:  Iran J Cancer Prev       Date:  2014

5.  Primary alveolar soft part sarcoma of the right femur and primary lymphoma of the left femur: A case report and literature review.

Authors:  Yiyuan Cao; Hanfei Zhang; Yanjuan Qu; Meiyan Liao
Journal:  Oncol Lett       Date:  2015-11-10       Impact factor: 2.967

6.  Metachronous Second Primary Malignancies in Known Breast Cancer Patients on 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography-Computerized Tomography in a Tertiary Care Center.

Authors:  Ranadheer Gupta Manthri; Sai Moulika Jeepalem; V S Krishna Mohan; D Bhargavi; Narendra Hulikal; Tekchand Kalawat
Journal:  Indian J Nucl Med       Date:  2019 Oct-Dec

7.  A Descriptive Study of the Types and Survival Patterns of Saudi Patients with Multiple Primary Solid Malignancies: A 30-Year Tertiary Care Center Experience.

Authors:  Moustafa S Alhamadh; Rakan B Alanazi; Sultan T Algarni; Ahmed Abdullah R Alhuntushi; Mohammed Qasim Alshehri; Yusra Sajid Chachar; Mohammad Alkaiyat; Fouad Sabatin
Journal:  Curr Oncol       Date:  2022-07-13       Impact factor: 3.109

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.